PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
复制标题
DOI：
10.1186/s40425-016-0153-x
复制
发表时间：
2016
影响因子：
10.9
通讯作者：
Rizvi NA
中科院分区：
文献类型：
--
作者：
Grigg C;Rizvi NA
在过去5年中，癌症免疫学的研究随着一系列癌症免疫治疗的突破而加速。阻断免疫细胞上的检查点分子PD-1和癌细胞上的PD-L1之间相互作用的各种单克隆抗体已被用于成功治疗非小细胞肺癌（NSCLC），包括一些持续多年的持久反应。两种药物nivolumab和pembrolizumab现在已被FDA批准用于某些铂类或靶向治疗失败或进展的患者，而靶向PD-L1的药物atezolizumab和durvalumab正在接近临床试验的最后阶段。尽管接受这些免疫治疗的患者子集的治疗结果令人印象深刻，但许多NSCLC患者对抗PD-1/PD-L1没有反应，并且鉴定生物标志物以选择这些患者仍然备受追捧。在这篇综述中，我们讨论了pembrolizumab，nivolumab和atezolizumab治疗NSCLC的最新临床试验结果，以及伴随诊断检测肿瘤PD-L1表达的意义。
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA approved for use in certain patients who have failed or progressed on platinum-based or targeted therapies while agents targeting PD-L1, atezolizumab and durvalumab, are approaching the final stages of clinical testing. Despite impressive treatment outcomes in a subset of patients who receive these immune therapies, many patients with NSCLC fail to respond to anti-PD-1/PD-L1 and the identification of a biomarker to select these patients remains highly sought after. In this review, we discuss the recent clinical trial results of pembrolizumab, nivolumab, and atezolizumab for NSCLC, and the significance of companion diagnostic testing for tumor PD-L1 expression.